Central administration of asprosin reduces baseline brain activity but does not attenuate 4-AP-induced epileptiform discharges: an in vivo electrophysiological study
Authors:
- Ömer Faruk KalkanÖKÖmer Faruk Kalkan
- Abdulhamit YildirimAYAbdulhamit Yildirim
- Osman AktaşOAOsman Aktaş
- Zafer ŞahinZŞZafer Şahin
- Selcen Aydin AbidinSASelcen Aydin Abidin
- Ali Faruk ÖzyaşarAÖAli Faruk Özyaşar
- Abdullah Kaan KurtAKAbdullah Kaan Kurt
- Samet Soner KüçükosmanSKSamet Soner Küçükosman
- İbRahim UzunIUİbRahim Uzun
- İsMail AbidinIAİsMail Abidin
- 12 November 2025
- journal article
- research article
- Published by Springer Nature in Biologia Futura
- Vol. 77 (1) , 155-164
Abstract
In the current study, we investigated the effects of central asprosin administration on baseline brain activity and 4-aminopyridine (4-AP) induced epileptiform activity. Additionally, we examined the effects of asprosin on electrocorticography (ECoG) band powers. Forty-two male Wistar rats were divided into six groups as follows: sham, 4-AP (2.5 mg/kg i.p.), asprosin 20 nmol (i.c.v.), asprosin 50 nmol (i.c.v.), asprosin 50 nmol (i.c.v.) posttreatment, and asprosin 50 nmol (i.c.v.) pre-treatment. Recordings lasting 60–70 min were conducted for all groups under ketamine/xylazine (90/10 mg/kg) anesthesia. In the posttreatment group, asprosin was injected 20 min after the induction of epileptiform activity. In the pre-treatment group, asprosin was injected after baseline recordings, and following a 20-min pre-treatment period, 4-AP was administered. 4-AP alone induced epileptiform activity in all animals, peaking at approximately the 30th minute. Asprosin significantly reduced ECoG power at doses of 20 nmol and 50 nmol. Furthermore, both doses of asprosin reduced alpha, beta, delta, theta, and gamma band activity in ECoG recordings at various time points. However, asprosin pre- and posttreatment had no significant effect on 4-AP-induced epileptiform activity. These findings suggest that asprosin modulates cortical excitability under physiological conditions but is ineffective in attenuating induced epileptiform activity.Keywords
This publication has 25 references indexed in Scilit:
- Targeting Adipokines: A Promising Therapeutic Strategy for EpilepsyNeurochemical Research, 2024
- Circulating asprosin concentrations in individuals with new-onset type 2 diabetes and prediabetesDiabetes Research and Clinical Practice, 2024
- Asprosin: its function as a novel endocrine factor in metabolic-related diseasesJournal of Endocrinological Investigation, 2024
- Intracerebroventricular asprosin administration strongly stimulates hypothalamic-pituitary-testicular axis in ratsMolecular and Cellular Endocrinology, 2021
- Brain concentrations of glutamate and GABA in human epilepsy: A reviewSeizure: European Journal of Epilepsy, 2021
- Phoenixin-14 reduces the frequency of interictal-like events in mice brain slicesExperimental Brain Research, 2021
- Activation of small conductance calcium-activated potassium channels suppresses seizure susceptibility in the genetically epilepsy-prone ratsNeuropharmacology, 2020
- Asprosin, a Fasting-Induced Glucogenic Protein HormoneCell, 2016
- The 4-aminopyridine in vitro epilepsy model analyzed with a perforated multi-electrode arrayNeuropharmacology, 2011
- The neurobiology of epilepsyCurrent Neurology and Neuroscience Reports, 2007